Meagan Anne Jacoby, MD - Washington ...

Dr. Meagan Jacoby, M.D., Ph.D.

Claim this profile

Washington University School of Medicine

Studies Myelodysplastic Syndrome
Studies Acute Myelogenous Leukemia
21 reported clinical trials
34 drugs studied

About Meagan Jacoby, M.D., Ph.D.

Education:

  • MD from Washington University School of Medicine.
  • PhD in Molecular Genetics and Genomics from Washington University School of Medicine.

Experience:

  • Specializes in leukemia at the Siteman Cancer Center.
  • Contributes to research, diagnosis, and treatment in her field.

Area of expertise

1Myelodysplastic Syndrome
Meagan Jacoby, M.D., Ph.D. has run 9 trials for Myelodysplastic Syndrome.
2Acute Myelogenous Leukemia
Meagan Jacoby, M.D., Ph.D. has run 9 trials for Acute Myelogenous Leukemia. Some of their research focus areas include:
FLT3 negative
CEBPA positive
Stage II

Affiliated Hospitals

Image of trial facility.
Washington University School Of Medicine
Image of trial facility.
Washington University

Clinical Trials Meagan Jacoby, M.D., Ph.D. is currently running

Image of trial facility.

Dendritic Cells

for Graft-versus-Host Disease

Dendritic cells (DCs) serve as sentries for the immune system. DCs recognize foreign compounds (antigens) in the body, which they internalize and process. When DCs uptake foreign antigens, they migrate to secondary lymphoid organs, where the processed antigens are presented to T cells. Various DC subsets with unique cell lineages, surface protein markers, and tissue localization determinants have been identified. For example, Langerhans cells (LCs) and interstitial dendritic cells (intDCs) are DCs found in stratified epithelia, such as the skin. Though both are expressed in the skin, they differ with respect to their origin and surface protein content and can activate distinct types of immune responses. They may also have different specificities for the capture of antigens and presentation to circulating T cells. To date, it is unknown what role, if any, the different DC populations that reside or repopulate in the skin play in the development and progression of skin graft-versus-host disease (GVHD) following bone marrow transplant.
Recruiting1 award N/A3 criteria
Image of trial facility.

ChromoSeq

for Myelodysplastic Syndrome

This is a single institution, prospective study of the whole genome sequencing assay, ChromoSeq. Using prospectively collected patient data, coupled with physician surveys, the investigators seek to determine the feasibility of implementing ChromoSeq in addition to standard genomic testing, for patients with the diagnosis of myelodysplastic syndrome (MDS).
Recruiting1 award N/A8 criteria

More about Meagan Jacoby, M.D., Ph.D.

Clinical Trial Related2 years of experience running clinical trials · Led 21 trials as a Principal Investigator · 7 Active Clinical Trials
Treatments Meagan Jacoby, M.D., Ph.D. has experience with
  • ChromoSeq
  • Cytokine Induced Memory-like NK Cell Adoptive Therapy
  • Fludarabine
  • Pacritinib
  • DEC-C
  • MyeloSeq-HD

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Meagan Jacoby, M.D., Ph.D. specialize in?
Is Meagan Jacoby, M.D., Ph.D. currently recruiting for clinical trials?
Are there any treatments that Meagan Jacoby, M.D., Ph.D. has studied deeply?
What is the best way to schedule an appointment with Meagan Jacoby, M.D., Ph.D.?
What is the office address of Meagan Jacoby, M.D., Ph.D.?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security